Dr. Tse-Wen Chang, Chairman
Please see Founder.
Dr. Hsing-Mao Art Chu, CEO
Dr. Chu earned his bachelor’s degree from Chang Gung University, followed by a master’s degree from National Yang Ming University and a Ph.D. from National Taiwan University. He conducted postdoctoral research at the Institute of Biological Chemistry, Academia Sinica, and in 2011 joined the laboratory of Distinguished Research Fellow Dr. Tse-Wen Chang at the Genomics Research Center, focusing on antibody engineering. His research centered on elucidating the molecular mechanisms underlying the interactions between CεmX and anti-CεmX.
In 2015, Dr. Chu joined Immunwork to lead R&D efforts using the proprietary T-E technology platform, advancing multiple drug programs. He has overseen six proof-of-concept successes, with two candidates entering human clinical trials, and is a co-inventor of more than 90 related patents. In 2023, Dr. Chu was appointed CEO of T-E Meds, while concurrently serving as Vice President of R&D at Immunwork. He currently serves as CEO of T-E Pharma, continuing to lead the company’s R&D and innovation efforts and driving novel drug candidates toward clinical development and commercialization.
Ms. Ying-Rong Lai, COO
Ms. Lai holds a Master’s degree in Biotechnology Management from National Taiwan University. Throughout her career, she has gained experience across multiple industries, including internal cost control and estimation, participation in industry tenders, and business management. She also spent several years in the higher education sector and engaged in both domestic and international trade, before ultimately entering the financial and accounting sector. She has demonstrated outstanding management experience across various business domains. With over a decade of experience in the financial industry, she has received multiple performance awards during her career.
In 2014, she was invited by Dr. Tse-Wen Chang to join the company’s executive team, assisting in the establishment of Immunwork and overseeing administrative and financial planning. She currently serves as Chief Operating Officer (COO) of T-E Pharma, responsible for company operations and overall management.
Dr. Ya-Shan Chuang, Senior Manager, Medical Affairs
Dr. Chuang obtained a B.Sc. degree in Life Science from National Tsing Hua University and a Ph.D. degree in the field of Biochemistry, Molecular and Cell Biology from Cornell University in the United States.
Before joining Immunwork in 2023, Dr. Chuang served as a project manager at Medigen Vaccine Biologics Corp., where he was responsible for the preclinical study of COVID-19 vaccine development and participated in clinical trials.
Currently, Dr. Chuang is mainly responsible for the planning of clinical trials of various drugs in Immunwork.
Dr. Wendy Mun-Teng Wong, Associate Director, Preclinical/Clinical Transition
Dr. Wong received her B.Sc. degree in Biomedicine in 2008 and Ph.D. in Biomedicine (Molecular and Cellular Biology) in 2013 from Universiti Sains Malaysia.
She did postdoctoral research on HCV replication pathway at the Institute of Biomedical Sciences, Academia Sinica in 2013-17.
Dr. Wong was recruited as associate research fellow in Immunwork in 2018 and was promoted to a project manager for programs on diabetes, obesity, and fatty liver diseases in 2020.
Dr. Ting Chen, Senior Manager, Strategy of Product Portfolio
Dr. Chen received her B.Sc. degree from National Taiwan Normal University in 2001, M.Sc. degree from National Taiwan University in 2003, and Ph.D. degree from National Tsing Hua University in 2010.
Before joining Immunwork in 2022, she did postdoctoral research on drug development against enterovirus A71 and SARS-CoV-2 at the Institute of Biomedical Sciences, Academia Sinica.
In her current position, Dr. Chen is responsible for communication with government agencies, planning investor awareness matters, and helping product portfolio strategies.
Dr. Jon Wright, Manager, IT and Preclinical/Clinical Studies
Dr. Jon received his Ph.D. in Chemistry and Biochemistry from the University of Essex, U.K. in 1996.
Following this he took up a postdoctoral position at the Institute of Biomedical Sciences, Academia Sinica where he researched protein-protein, protein-DNA and protein-small molecule interactions with an emphasis on complex structural modeling, dynamics and design.
During his time at IBMS he operated as both researcher and lab manager until 2022 when he joined Immunwork to take up the position of manager of IT and preclinical/clinical studies.